Pimecrolimus

Pimecrolimus 1% cream (Elidel) is the milder of the two Topical Calcineurin Inhibitors (TCIs). It is used for mild to moderate Atopic Dermatitis, especially on the face, eyelids and neck, where parents and doctors want to limit Topical Corticosteroids. Like Tacrolimus it blocks calcineurin and damps T-cell inflammation without thinning the skin (Skin Atrophy). It is a cream rather than an ointment, so it suits the face and weeping-free flexures. It is used twice daily for flares or twice weekly as maintenance (Weekend Therapy) (National Eczema Society).

Pimecrolimus [part-of] Topical Calcineurin Inhibitors Pimecrolimus [treats] Atopic Dermatitis Pimecrolimus [relates] Topical Corticosteroids

Licensing ages: the TCI with a toddler licence. In the UK, Elidel is licensed from 3 months of age (National Eczema Society; PCDS). That makes it the only TCI licensed for a 1-year-old there. US labelling (FDA approval 2001) and NICE CG57 / TA82 (2004) refer to children aged 2 and over. NICE recommends it for moderate facial and neck eczema in children 2 and over that TCS have not controlled. In South Africa it is registered from age 2, but the South African Eczema Guidance algorithm uses TCIs first-line on sensitive sites, and its experts consider pimecrolimus safe under 2 (Kannenberg 2020). Expert consensus has argued since 2015 that it need not be restricted to over-2s (Taieb, cited by PCDS).

NICE CG57 [regulates] Pimecrolimus FDA [regulates] Pimecrolimus South African Eczema Guidance [supports] Pimecrolimus

Conflict: [NICE TA82/CG57, 2004] recommends pimecrolimus only for children aged 2 and over. [National Eczema Society, 2023; PCDS, n.d.] say the UK Elidel licence starts at 3 months. NICE guidance predates the licence change. Unresolved — already in proactive-therapy open_questions.

Safety data in children. The PEER Registry followed 7,457 US children aged 2–17 who had used pimecrolimus (26,792 person-years). It recorded 5 cancers and no skin cancers. The standardised incidence ratio was 1.2 (95% CI 0.5–2.8) for all cancers and 2.9 (0.7–11.7) for lymphoma, neither significant (Margolis, JAMA Dermatol 2015). The Devasenapathy meta-analysis (2023) found pimecrolimus OR 1.05 for any cancer, with similar results in infants. Health Canada removed its boxed warning for pimecrolimus in 2019, and a 2026 FAERS study found no lymphoma signal. The 2006 US boxed warning remains, and Lam et al. (2021) found a raised relative lymphoma risk across TCIs (see Topical Calcineurin Inhibitors for the conflict).

PEER Registry [supports] Pimecrolimus FDA [opposes] Pimecrolimus

Side effects, burning and sun advice. Burning or a warm stinging feeling for 15–20 minutes after application is the most common side effect. It usually fades within the first week (National Eczema Society). It should not be used on infected skin (Impetigo, cold sores, Eczema Herpeticum) or under Wet Wrap Therapy, and sun protection is advised on treated areas. Pimecrolimus is also used off-label for Perioral Dermatitis in children after facial steroid use. There it reduces severity quickly but does not shorten time to clearance (Hall & Reichenberg 2010). A parent on r/toddlertips reported a dermatologist prescribing pimecrolimus 1% for a 2-year-old’s perioral rash, with nightly gentle washing and no fluoridated toothpaste; the rash was “way better after one week” but not gone (evidence: anecdotal).

Pimecrolimus [treats] Perioral Dermatitis Pimecrolimus [relates] Eczema Herpeticum

Not on infected skin

Do not apply pimecrolimus to skin with impetigo, cold sores, or punched-out sores with fever (possible eczema herpeticum). Seek same-day medical review.

Cost. Pimecrolimus is the most expensive common topical. US retail is about $195–212 per 30 g (coupon about $70–82), and a UK NHS price was not retrieved (Cost of Eczema Care).

Pimecrolimus [relates] Cost of Eczema Care

What parents report (evidence: anecdotal). Parents mostly name tacrolimus rather than pimecrolimus. One US parent asked for “a tacrolimus or pimecrolimus prescription” for a toddler under 2 and was refused because it “wasn’t approved for under 2”, and was told a dermatologist would have to prescribe off-label (r/eczema). See Parent Experiences.

Pimecrolimus [relates] Parent Experiences

Connections

• Topical Calcineurin Inhibitors — one of two TCIs, source: National Eczema Society; PCDS
• PEER Registry — post-marketing safety cohort, source: Margolis JAMA Dermatol 2015
• South African Eczema Guidance — SA-registered ≥2 y; algorithm uses it first-line on face, source: Kannenberg 2020
• Tacrolimus — stronger TCI, licensed from 2 y, source: National Eczema Society
• NICE CG57 — TA82 moderate face/neck eczema ≥2 y, source: NICE CG57
• Perioral Dermatitis — off-label use after facial steroids, source: Hall & Reichenberg 2010
• Cost of Eczema Care — ~$195–212 per 30 g US retail, source: GoodRx; Rx.com
• FDA — 2001 approval ≥2 y; 2006 boxed warning, source: Arcuri 2026
• Parent Experiences — parent reports (anecdotal), source: round-10 forum threads